News

Activation of an embryo's genome does not happen all at once; instead it follows a specific pattern controlled primarily by the various sizes of its cells.

Scientists in the FinnBrain research project of the University of Turku, Finland, discovered that the gut microbes of a 2.5-month-old infant are associated with temperament traits manifested at six months of age.

Cohesin mutations have been identified in some types of cancer and in rare diseases referred to as cohesinopathies. Now, scientsits describe new functions of cohesin in mouse embryonic stem cells that might help understand and address the causes of these disorders.

Researchers have identified a brain circuit in the basal forebrain that suppresses appetite when it's active and stimulates feeding behavior when it's inactive. The researchers observed mice displaying dramatically altered feeding behaviors after activating the circuit. Researchers say the study could give insight into human eating disorders.

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

Researchers at ETH Zurich have discovered redundancies in the biochemical signalling pathways of immune cells. This finding has important implications for advances in cancer immunotherapy, among other areas.

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.

A therapeutic gene delivered into the spinal canal of infant rhesus monkeys was still being expressed after nearly 4 years, with no evidence of acute or chronic neuronal toxicity, according to a new study

In malignant tumors, the cells usually proliferate quickly and uncontrollably. Researchers have discovered that two important regulators of cell division can interact in this process. If this is the case, affected patients have particularly poor chances of survival. The long-term goal is to suppress tumor growth by blocking the interaction.

An antibody has been identified that broadly inhibits multiple strains of pandemic norovirus, a major step forward in the development of an effective vaccine for the dreaded stomach virus.